The Next Ozempic? Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test

Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday. Continue Reading

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.